Lucerastat, an iminosugar for substrate reduction therapy in Fabry disease: preclinical evidence by Priestman, D, Welford, R, Platt, F, Muhlemann, A, Garzotti, M, Deymier, C, Ertel, E, Iglarz, M, Baldoni, D, Probst, M

Lucerastat, an iminosugar for substrate reduction therapy in Fabry Disease: Preclinical evidence by Welford, R, Mühleman, A, Priestman, D, Garzotti, M, Deymier, C, Ertel, E, Iglarz, M, Morand, O, Priestman, D, Platt, F, Probst, M

An international multicentre validation experiment for MOG antibodies by Reindl, M, Schanda, K, Woodhall, M, Tea, F, Ramanathan, S, Teegen, B, Sagen, J, Fryer, J, Mills, J, Mindorf, S, Ritter, N, Krummrei, U, Stoecker, W, Eggert, J, Rostasy, K, Berger, T, Irani, S, Dale, R, Probst, C, Brilot, F, Probst, M, Pittock, S, Waters, P

Epidemiology and clinical features of vivax malaria imported to Europe: Sentinel surveillance data from TropNetEurop by Malvy DJM, Kotlowski A, Iversen J, Knobloch J, Kapaun A, Kollaritsch H, Hatz C, Holthoff-Stich ML, Laferl H, Myrvang B, Schmid ML, Puente S, Hellgren U, Bisoffi Z, Lopez-Velez R, Matteelli A, McWhinney P, Björkman A, Clerinx J, Behrens RH, Gjørup I, Beran J, Schunk M, Zoller T, Probst M, Gascon J, Jelinek T, Mühlberger N, Kern P, Fry G, Siikamaki H, Schulze MH, Soula G, Paul M, Prat J Gómez i, Lehmann V, Bouchaud O, Cunha S da, Atouguia J, Boecken G

Get full text